top of page

October 11, 2023

Crossbow Therapeutics Announces Formation of Its Scientific Advisory Board

Cambridge, MA (October 11, 2023) – We are proud to announce our Scientific Advisory Board, a group of outstanding research and industry experts who will complement the deep expertise of our Senior Leadership Team and Board of Directors. “Crossbow Therapeutics is honored to have such an accomplished and dedicated group of scientific advisors to help guide us on our mission to expand the reach and impact of antibody therapeutics for those living with cancer,” said Dmitri Wiederschain, Chief Scientific Officer of Crossbow Therapeutics.

Patrick Baeuerle, Ph.D. – Dr. Patrick Baeuerle is co-founder and Chief Scientific Advisor of Cullinan Oncology, as well as an Executive Partner at MPM BioImpact. Dr. Baeuerle has co-founded eight MPM oncology portfolio companies, including Crossbow Therapeutics, and brings extensive immuno-oncology expertise. 


Robert Iannone, MD, M.S.C.E. – Dr. Robert Iannone serves as Jazz Pharmaceutical’s Executive Vice President and Global Head of Research and Development. He brings vast expertise in preclinical and clinical drug development across therapeutic areas and phases of development. 


Daniel J. Powell Jr., Ph.D. – Dr. Daniel J. Powell Jr. currently serves as the Scientific Director of Immunotherapy in the Division of Gynecologic Oncology and as Professor in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania. He brings significant expertise on solid tumor immunobiology, translational immunotherapy, public neoantigen targeting, biomarker discovery, tumor microenvironment, T cell therapy and TCR-mimetics. 


Katarina Radošević, Ph.D. – Dr. Katarina Radošević is a creative strategic leader with ample expertise and experience in biologics innovation. She is the founder of Kathoro, a consulting firm providing independent guidance on science, organization and strategy necessary for successful and innovative biologics enterprises. She previously held senior leadership positions in biologics R&D and technology innovation at Crucell, J&J, Sanofi, and Lonza.

Roland Strong, Ph.D. – Dr. Roland Strong serves as Professor in the Basic Sciences Division, Professor in the Vaccine and Infectious Disease Division, and a member of the Translational Data Science Integrated Research Center (TDS IRC) at the Fred Hutchinson Cancer Research Center (the Hutch). He brings substantial expertise in biophysics, structural biology, protein engineering and immuno-peptidomics.

James A. Wells, Ph.D. – Dr. James A. Wells is a Professor at the Department of Pharmaceutical Chemistry at the University of California San Francisco (UCSF). Dr. Wells is a serial entrepreneur and co-founder of multiple biotech companies.  He brings considerable expertise in antibody discovery, signal transduction and preclinical cancer models. 

Forest White, Ph.D. – Dr. Forest White serves as the Ned C. and Janet Bemis Rice Professor in the Department of Biological Engineering at the Massachusetts Institute of Technology (MIT). He brings a wealth of expertise in immuno-peptidomics, mass spectrometry and signal transduction.  

Re: Scientific Advisory Board Full Bios

Investor Contact:
Crossbow Therapeutics, Inc. 
Geraldine Paulus, Co-Founder, Vice President of Corporate Development an
d Operations 

Media Contact: 
Corey Carmichael 
(862) 260-7929 

bottom of page